Tags

Type your tag names separated by a space and hit enter

Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Nutr Metab Cardiovasc Dis 2008; 18(8):523-30NM

Abstract

BACKGROUND AND AIM

Epicardial fat (EF), a true visceral adipose tissue (VAT) deposited around the heart, is considered as possible cardiovascular risk indicator, in view of its ability to produce and release several inflammatory adipo-cytokines. It is still not known whether increased cardiac adiposity is related to increased inflammatory adipo-cytokines in obesity. The aim of this study was to evaluate whether echocardiographic EF thickness, an indicator of cardiac adiposity, is related to circulating levels of inflammatory adipo-cytokines such as visfatin and plasminogen activator inhibitor-1 (PAI-1) in visceral obesity.

METHODS AND RESULTS

EF thickness (measured by echocardiography), visfatin, PAI-1 antigen and some inflammatory markers were studied in 42 women, 27 of them severely obese (OB) (BMI 43.5+/-4.8 kg/m(2)) but with no apparent complications, and 15 normal-weight controls. Abdominal VAT in the OB was assessed by computed tomography. OB had thicker EF and higher visfatin and PAI-1 antigen concentrations than controls (P<0.0001). EF thickness, log-visfatin and log-PAI-1 antigen concentrations directly correlated with VAT (P<0.0001). Log-visfatin and log-PAI-1 antigen were correlated with EF thickness even after adjusting for indices of fat distribution (P<0.01 and P<0.001 respectively). Moreover, when dividing OB on the basis of median EF thickness, women with greater EF thickness had more VAT and higher adipo-cytokine concentrations and inflammatory markers.

CONCLUSIONS

This study suggests that EF thickness, an indicator of cardiac adiposity, may be significantly related to inflammatory adipo-cytokines in visceral-obese patients. This suggests EF might be used as an easy and reliable marker of visceral adiposity and inflammation and as a cardiovascular risk indicator.

Authors+Show Affiliations

Endocrinology Unit, Department of Medical and Surgical Sciences, University of Milan, IRCCS Policlinico San Donato, via Morandi 30, I-20097 San Donato Milanese, Italy. alexis.malavazos@libero.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18083357

Citation

Malavazos, Alexis E., et al. "Epicardial Fat Thickness: Relationship With Plasma Visfatin and Plasminogen Activator Inhibitor-1 Levels in Visceral Obesity." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 18, no. 8, 2008, pp. 523-30.
Malavazos AE, Ermetici F, Cereda E, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis. 2008;18(8):523-30.
Malavazos, A. E., Ermetici, F., Cereda, E., Coman, C., Locati, M., Morricone, L., ... Ambrosi, B. (2008). Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 18(8), pp. 523-30.
Malavazos AE, et al. Epicardial Fat Thickness: Relationship With Plasma Visfatin and Plasminogen Activator Inhibitor-1 Levels in Visceral Obesity. Nutr Metab Cardiovasc Dis. 2008;18(8):523-30. PubMed PMID: 18083357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. AU - Malavazos,Alexis E, AU - Ermetici,Federica, AU - Cereda,Emanuele, AU - Coman,Calin, AU - Locati,Massimo, AU - Morricone,Lelio, AU - Corsi,Massimiliano M, AU - Ambrosi,Bruno, Y1 - 2008/02/20/ PY - 2007/07/02/received PY - 2007/08/21/revised PY - 2007/09/06/accepted PY - 2007/12/18/pubmed PY - 2009/2/14/medline PY - 2007/12/18/entrez SP - 523 EP - 30 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 18 IS - 8 N2 - BACKGROUND AND AIM: Epicardial fat (EF), a true visceral adipose tissue (VAT) deposited around the heart, is considered as possible cardiovascular risk indicator, in view of its ability to produce and release several inflammatory adipo-cytokines. It is still not known whether increased cardiac adiposity is related to increased inflammatory adipo-cytokines in obesity. The aim of this study was to evaluate whether echocardiographic EF thickness, an indicator of cardiac adiposity, is related to circulating levels of inflammatory adipo-cytokines such as visfatin and plasminogen activator inhibitor-1 (PAI-1) in visceral obesity. METHODS AND RESULTS: EF thickness (measured by echocardiography), visfatin, PAI-1 antigen and some inflammatory markers were studied in 42 women, 27 of them severely obese (OB) (BMI 43.5+/-4.8 kg/m(2)) but with no apparent complications, and 15 normal-weight controls. Abdominal VAT in the OB was assessed by computed tomography. OB had thicker EF and higher visfatin and PAI-1 antigen concentrations than controls (P<0.0001). EF thickness, log-visfatin and log-PAI-1 antigen concentrations directly correlated with VAT (P<0.0001). Log-visfatin and log-PAI-1 antigen were correlated with EF thickness even after adjusting for indices of fat distribution (P<0.01 and P<0.001 respectively). Moreover, when dividing OB on the basis of median EF thickness, women with greater EF thickness had more VAT and higher adipo-cytokine concentrations and inflammatory markers. CONCLUSIONS: This study suggests that EF thickness, an indicator of cardiac adiposity, may be significantly related to inflammatory adipo-cytokines in visceral-obese patients. This suggests EF might be used as an easy and reliable marker of visceral adiposity and inflammation and as a cardiovascular risk indicator. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/18083357/Epicardial_fat_thickness:_relationship_with_plasma_visfatin_and_plasminogen_activator_inhibitor_1_levels_in_visceral_obesity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(07)00171-8 DB - PRIME DP - Unbound Medicine ER -